Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.45 |
| ▸ | GFER | P55789 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23088651 | 1.00 | PDE4D (0.45) | PDE4DGFERKMT2AMEN1PROKR1 | |
| SCHEMBL23098519 | 0.92 | PDE4D (0.50) | PDE4DGFERKMT2AMEN1 | |
| SCHEMBL29769942 | 0.92 | PDE4D (0.50) | PDE4DGFERKMT2AMEN1 | |
| SCHEMBL23098523 | 0.85 | PDE4D (0.48) | PDE4D | |
| SCHEMBL23088634 | 0.84 | PDE4D (0.59) | PDE4D | |
| SCHEMBL23088635 | 0.84 | PDE4D (0.59) | PDE4D | |
| SCHEMBL23088623 | 0.81 | PDE4D (0.64) | PDE4DKMT2A | |
| SCHEMBL23088624 | 0.81 | PDE4D (0.64) | PDE4DKMT2A | |
| SCHEMBL30712005 | 0.81 | PDE4D (0.64) | PDE4DKMT2A | |
| SCHEMBL23088649 | 0.77 | PDE4D (0.60) | PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724196-B9 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-03-22 | — | — | EP | claimed |
| EP-3724196-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2022-11-16 | — | — | EP | claimed |
| US-11384096-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-07-12 | — | — | US | claimed |
| US-20210079012-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-18 | — | — | US | claimed |
| US-11981681-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2024-05-14 | — | — | US | disclosed |
| CN-111727191-B | Substituted azetidine dihydro-thienopyridines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230087354-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2023-03-23 | — | — | US | disclosed |
| EP-3724196-B9 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-03-22 | — | — | EP | disclosed |
| EP-3724196-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2022-11-16 | — | — | EP | disclosed |
| US-11384096-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-07-12 | — | — | US | disclosed |
| US-20210079012-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-18 | — | — | US | disclosed |
| CN-111727191-A | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384096-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | PDE2A, PDE3A, PDE3B | PDE4D 12/4885GFER 2535/4885KMT2A 2737/4885 |
| US-11981681-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | PDE2A, PDE3A, PDE3B | PDE4D 12/4885GFER 2535/4885KMT2A 2737/4885 |
| US-20210079012-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE3A, PDE3B | PDE4D 12/4885GFER 2535/4885KMT2A 2737/4885 |
| US-20230087354-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE3A, PDE3B | PDE4D 12/4885GFER 2535/4885KMT2A 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.